Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 20, 2009. The filing addresses a Regulation FD disclosure regarding the status of a bid submitted to the U.S. Department of Health and Human Services (DHHS) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory update regarding a potential government contract.
Material Changes and Contract Status
- Original Timeline: The DHHS issued Request for Proposal (RFP-BARDA-08-15) on February 29, 2008, with an initial award date of September 26, 2008, later extended to December 31, 2008.
- Current Status: The award date has been delayed further. Based on recent communications, the Company believes an award may be made during the first half of April 2009.
- Uncertainty: The Company explicitly states there is no assurance that the timeline will not be extended again or that the contract will be awarded.
Outlook, Risks, and Management Commentary
Management commentary indicates that while the Company anticipates a potential award in early April 2009, the outcome remains uncertain. The primary risk identified is the potential for further delays in the government procurement process or the possibility that the Company will not be selected for the contract. The information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the actual award date of the DHHS contract, if awarded, against the projected "first half of April 2009" timeline.
- Confirm whether the contract award materializes, given the Company's explicit disclaimer of assurance.
- Monitor for subsequent filings if the award timeline is extended beyond April 2009.
- Note the discrepancy between the requested company name (Altimmune, Inc.) and the actual registrant (PharmAthene, Inc.).